| Symbol | BHVN |
|---|---|
| Name | BIOHAVEN LTD. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 215 CHURCH STREET, NEW HAVEN, Connecticut, 06510, United States |
| Telephone | +1 203 404-0410 |
| Fax | — |
| — | |
| Website | https://www.biohaven.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001935979 |
| Description | Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Additional info from NASDAQ: |
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Read moreBiohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Read moreFederal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
Read moreNew Form 3 - Biohaven Ltd. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0002150506-26-000002 <b>Size:</b> 276 KB
Read moreNew Form SCHEDULE 13G - Biohaven Ltd. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005259 <b>Size:</b> 8 KB
Read moreBiohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Read more